We are live on ! Find out more
SPHS

Sophiris Bio, Inc.
SPHS

Delisted

SPHS was delisted on the 11th of March, 2020.

31 hedge funds and large institutions have $4.07M invested in Sophiris Bio, Inc. in 2017 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 6 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 6

0% more funds holding

Funds holding: 3131 (0)

0% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 5

21% less capital invested

Capital invested by funds: $5.18M → $4.07M (-$1.11M)

84% less call options, than puts

Call options by funds: $40K | Put options by funds: $248K

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
31
Holders Change
Holders Change %
0%
% of All Funds
0.77%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
5
Increased
10
Reduced
6
Closed
5
Calls
$40K
Puts
$248K
Net Calls
-$208K
Net Calls Change
+$27K

SPHS Hedge Fund Activity: Q2 2017 in Review

31 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Sophiris Bio, Inc. (SPHS) for Q2 2017, worth a combined $4.07M — down 21% from $5.18M a quarter earlier.

Fund positioning in SPHS was balanced in Q2 2017: 5 funds opened new positions, 5 closed out, 10 added to existing stakes and 6 trimmed.

The largest buyer was BlackRock, opening a new position worth an estimated $197K. The largest seller was Sofinnova Management VIII, exiting entirely with an estimated $566K sold.

  • 31 institutional investors held Sophiris Bio, Inc. (SPHS) as of Q2 2017, unchanged from Q1 2017.
  • Funds reported $4.07M of Sophiris Bio, Inc. stock for Q2 2017, down 21% quarter-over-quarter.
  • 5 funds opened new Sophiris Bio, Inc. positions in Q2 2017 and 5 closed out, a net change of 0 holders.
  • The largest Sophiris Bio, Inc. buyer in Q2 2017 was BlackRock, an estimated $197K added.
  • The largest Sophiris Bio, Inc. seller in Q2 2017 was Sofinnova Management VIII, an estimated $566K sold.

Based on aggregated 13F filings for Q2 2017.